Which has preferable earnings and valuation, BVS or EMBC?

Embecta has higher revenue and earnings than Bioventus. Embecta is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Bioventus $568.09M 1.26 $22.73M $0.41 20.87 Embecta $1.04B 0.18 $95.40M $1.90 1.64

Is BVS or EMBC more profitable?

Embecta has a net margin of 10.73% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Bioventus 4.94% 29.97% 9.52% Embecta 10.73% -23.96% 14.12%

Does the media refer more to BVS or EMBC?

In the previous week, Bioventus had 2 more articles in the media than Embecta. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat Bioventus' score of 1.00 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Bioventus 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor SSII or EMBC?

In the previous week, SS Innovations International and SS Innovations International both had 2 articles in the media. Embecta's average media sentiment score of 1.47 beat SS Innovations International's score of 1.16 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SS Innovations International 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, CBLL or EMBC?

Embecta has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CeriBell $89.06M 7.72 -$53.41M -$1.63 N/A Embecta $1.04B 0.18 $95.40M $1.90 1.64

Is CBLL or EMBC more profitable?

Embecta has a net margin of 10.73% compared to CeriBell's net margin of -63.51%. Embecta's return on equity of -23.96% beat CeriBell's return on equity. Company Net Margins Return on Equity Return on Assets CeriBell -63.51% -38.19% -30.92% Embecta 10.73% -23.96% 14.12%

Does the media favor CBLL or EMBC?

In the previous week, CeriBell had 3 more articles in the media than Embecta. MarketBeat recorded 5 mentions for CeriBell and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat CeriBell's score of 0.56 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CeriBell 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, SIBN or EMBC?

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio SiBone $200.93M 3.43 -$18.90M -$0.39 N/A Embecta $1.04B 0.18 $95.40M $1.90 1.64

Is SIBN or EMBC more profitable?

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets SiBone -8.10% -9.56% -7.06% Embecta 10.73% -23.96% 14.12%

Does the media favor SIBN or EMBC?

In the previous week, SiBone had 1 more articles in the media than Embecta. MarketBeat recorded 3 mentions for SiBone and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat SiBone's score of 0.60 indicating that Embecta is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SiBone 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, EMBC or BBNX?

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Embecta $1.04B 0.18 $95.40M $1.90 1.64 Beta Bionics $100.25M 6.28 -$73.20M -$1.51 N/A

Is EMBC or BBNX more profitable?

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity. Company Net Margins Return on Equity Return on Assets Embecta 10.73% -23.96% 14.12% Beta Bionics -60.27% -23.00% -20.55%

Does the media refer more to EMBC or BBNX?

In the previous week, Beta Bionics had 7 more articles in the media than Embecta. MarketBeat recorded 9 mentions for Beta Bionics and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat Beta Bionics' score of 0.22 indicating that Embecta is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Embecta 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Beta Bionics 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral

Embecta (EMBC) Competitors

$3.12 +0.02 (+0.52%)

As of 10:46 AM Eastern

Compare

EMBC vs. BVS, SSII, CBLL, SIBN, and BBNX

Should you buy Embecta stock or one of its competitors? MarketBeat compares Embecta with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Embecta include Bioventus (BVS), SS Innovations International (SSII), CeriBell (CBLL), SiBone (SIBN), and Beta Bionics (BBNX). These companies are all part of the "medical equipment" industry.

How does Embecta compare to Bioventus?

Bioventus (NASDAQ:BVS) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the superior business? We will compare the two businesses based on the strength of their media sentiment, risk, institutional ownership, analyst recommendations, dividends, valuation, earnings and profitability.

Embecta has a net margin of 10.73% compared to Bioventus' net margin of 4.94%. Bioventus' return on equity of 29.97% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bioventus	4.94%	29.97%	9.52%
Embecta	10.73%	-23.96%	14.12%

Bioventus currently has a consensus price target of $14.00, suggesting a potential upside of 63.65%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 253.02%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than Bioventus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bioventus	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.00
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

In the previous week, Bioventus had 2 more articles in the media than Embecta. MarketBeat recorded 4 mentions for Bioventus and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat Bioventus' score of 1.00 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Bioventus	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Embecta has higher revenue and earnings than Bioventus. Embecta is trading at a lower price-to-earnings ratio than Bioventus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bioventus	$568.09M	1.26	$22.73M	$0.41	20.87
Embecta	$1.04B	0.18	$95.40M	$1.90	1.64

62.9% of Bioventus shares are held by institutional investors. Comparatively, 93.8% of Embecta shares are held by institutional investors. 33.0% of Bioventus shares are held by company insiders. Comparatively, 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Bioventus has a beta of 0.67, indicating that its stock price is 33% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

Summary

Embecta beats Bioventus on 9 of the 17 factors compared between the two stocks.

How does Embecta compare to SS Innovations International?

SS Innovations International (NASDAQ:SSII) and Embecta (NASDAQ:EMBC) are both small-cap medical equipment companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.

Embecta has higher revenue and earnings than SS Innovations International. SS Innovations International is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SS Innovations International	$42.49M	16.18	-$12.13M	-$0.05	N/A
Embecta	$1.04B	0.18	$95.40M	$1.90	1.64

In the previous week, SS Innovations International and SS Innovations International both had 2 articles in the media. Embecta's average media sentiment score of 1.47 beat SS Innovations International's score of 1.16 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SS Innovations International	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

SS Innovations International has a beta of -1.89, indicating that its stock price is 289% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

SS Innovations International presently has a consensus target price of $7.00, suggesting a potential upside of 103.73%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 253.02%. Given Embecta's stronger consensus rating and higher possible upside, analysts clearly believe Embecta is more favorable than SS Innovations International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SS Innovations International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Embecta has a net margin of 10.73% compared to SS Innovations International's net margin of -20.69%. SS Innovations International's return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SS Innovations International	-20.69%	-23.00%	-13.18%
Embecta	10.73%	-23.96%	14.12%

Summary

Embecta beats SS Innovations International on 12 of the 14 factors compared between the two stocks.

How does Embecta compare to CeriBell?

CeriBell (NASDAQ:CBLL) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations.

Embecta has a net margin of 10.73% compared to CeriBell's net margin of -63.51%. Embecta's return on equity of -23.96% beat CeriBell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CeriBell	-63.51%	-38.19%	-30.92%
Embecta	10.73%	-23.96%	14.12%

93.8% of Embecta shares are held by institutional investors. 20.1% of CeriBell shares are held by insiders. Comparatively, 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

CeriBell has a beta of 0.85, indicating that its stock price is 15% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, indicating that its stock price is 17% less volatile than the broader market.

In the previous week, CeriBell had 3 more articles in the media than Embecta. MarketBeat recorded 5 mentions for CeriBell and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat CeriBell's score of 0.56 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CeriBell	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

CeriBell currently has a consensus price target of $22.20, suggesting a potential upside of 22.49%. Embecta has a consensus price target of $11.00, suggesting a potential upside of 253.02%. Given Embecta's higher probable upside, analysts plainly believe Embecta is more favorable than CeriBell.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CeriBell	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.83
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

Embecta has higher revenue and earnings than CeriBell. CeriBell is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CeriBell	$89.06M	7.72	-$53.41M	-$1.63	N/A
Embecta	$1.04B	0.18	$95.40M	$1.90	1.64

Summary

Embecta beats CeriBell on 10 of the 17 factors compared between the two stocks.

How does Embecta compare to SiBone?

SiBone (NASDAQ:SIBN) and Embecta (NASDAQ:EMBC) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their media sentiment, earnings, dividends, valuation, institutional ownership, profitability, risk and analyst recommendations.

In the previous week, SiBone had 1 more articles in the media than Embecta. MarketBeat recorded 3 mentions for SiBone and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat SiBone's score of 0.60 indicating that Embecta is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
SiBone	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

SiBone presently has a consensus target price of $23.00, suggesting a potential upside of 48.14%. Embecta has a consensus target price of $11.00, suggesting a potential upside of 253.02%. Given Embecta's higher probable upside, analysts clearly believe Embecta is more favorable than SiBone.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
SiBone	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.71
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40

98.1% of SiBone shares are owned by institutional investors. Comparatively, 93.8% of Embecta shares are owned by institutional investors. 3.9% of SiBone shares are owned by insiders. Comparatively, 1.3% of Embecta shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

SiBone has a beta of 0.7, suggesting that its share price is 30% less volatile than the broader market. Comparatively, Embecta has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Embecta has a net margin of 10.73% compared to SiBone's net margin of -8.10%. SiBone's return on equity of -9.56% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
SiBone	-8.10%	-9.56%	-7.06%
Embecta	10.73%	-23.96%	14.12%

Embecta has higher revenue and earnings than SiBone. SiBone is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
SiBone	$200.93M	3.43	-$18.90M	-$0.39	N/A
Embecta	$1.04B	0.18	$95.40M	$1.90	1.64

Summary

Embecta beats SiBone on 9 of the 16 factors compared between the two stocks.

How does Embecta compare to Beta Bionics?

Embecta (NASDAQ:EMBC) and Beta Bionics (NASDAQ:BBNX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, dividends, institutional ownership, earnings, valuation, risk, media sentiment and analyst recommendations.

Embecta has a net margin of 10.73% compared to Beta Bionics' net margin of -60.27%. Beta Bionics' return on equity of -23.00% beat Embecta's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Embecta	10.73%	-23.96%	14.12%
Beta Bionics	-60.27%	-23.00%	-20.55%

In the previous week, Beta Bionics had 7 more articles in the media than Embecta. MarketBeat recorded 9 mentions for Beta Bionics and 2 mentions for Embecta. Embecta's average media sentiment score of 1.47 beat Beta Bionics' score of 0.22 indicating that Embecta is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Embecta	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Beta Bionics	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

93.8% of Embecta shares are owned by institutional investors. 1.3% of Embecta shares are owned by company insiders. Comparatively, 5.3% of Beta Bionics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Embecta has higher revenue and earnings than Beta Bionics. Beta Bionics is trading at a lower price-to-earnings ratio than Embecta, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Embecta	$1.04B	0.18	$95.40M	$1.90	1.64
Beta Bionics	$100.25M	6.28	-$73.20M	-$1.51	N/A

Embecta has a beta of 0.83, indicating that its share price is 17% less volatile than the broader market. Comparatively, Beta Bionics has a beta of 3.4, indicating that its share price is 240% more volatile than the broader market.

Embecta presently has a consensus price target of $11.00, suggesting a potential upside of 253.02%. Beta Bionics has a consensus price target of $19.70, suggesting a potential upside of 39.52%. Given Embecta's higher possible upside, analysts plainly believe Embecta is more favorable than Beta Bionics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Embecta	3 Sell rating(s)	2 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.40
Beta Bionics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64

Summary

Embecta beats Beta Bionics on 9 of the 17 factors compared between the two stocks.

Get Embecta News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding EMBC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

EMBC vs. The Competition

Export

Metric	Embecta	Medical Services Industry	Medical Sector	NASDAQ Exchange
Market Cap	$184.81M	$8.88B	$6.49B	$12.31B
Dividend Yield	1.30%	1.71%	2.67%	5.66%
P/E Ratio	1.64	24.27	24.05	24.76
Price / Sales	0.18	24.43	542.61	168.32
Price / Cash	0.77	13.73	27.48	37.92
Price / Book	-0.28	5.55	10.69	6.90
Net Income	$95.40M	$177.22M	$3.57B	$337.45M
7 Day Performance	-6.71%	2.46%	1.56%	2.84%
1 Month Performance	-0.76%	10.71%	2.49%	4.78%
1 Year Performance	-67.41%	6.44%	26.51%	33.08%

Embecta Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
EMBC Embecta	4.3569 of 5 stars	$3.12 +0.5%	$11.00 +253.0%	-67.6%	$184.81M	$1.04B	1.64	1,850	Positive News
BVS Bioventus	4.4725 of 5 stars	$9.29 +3.8%	$14.00 +50.7%	N/A	$773.58M	$568.09M	22.59	1,200	Positive News Gap Up
SSII SS Innovations International	2.9454 of 5 stars	$3.71 +5.1%	$7.00 +88.7%	-5.1%	$742.68M	$42.49M	N/A	4	Positive News Gap Up
CBLL CeriBell	2.629 of 5 stars	$18.78 +3.5%	$22.20 +18.2%	+6.9%	$710.24M	$89.06M	N/A	N/A
SIBN SiBone	2.3352 of 5 stars	$15.43 +3.0%	$23.00 +49.1%	-11.5%	$679.89M	$200.93M	N/A	350

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:EMBC) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Embecta (EMBC) Competitors